SpringerLink
Log in

Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The prognosis of non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is unclear. To assess the prognosis of NSCLC patients with ILD treated with platinum-based chemotherapy, we retrospectively analyzed the clinical course of those with ILD.

Methods

One hundred and four NSCLC patients with ILD treated with platinum-based chemotherapy at Shizuoka Cancer Center between August 2002 and June 2013 were retrospectively reviewed.

Results

The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61 %). The overall response rate was 38 % in 104 NSCLC patients with ILD treated with platinum-based chemotherapy. In all patients, median progression-free survival and overall survival were 4.8 and 9.9 months, respectively. During first-line platinum-based chemotherapy, 9 % of the 104 patients with ILD developed chemotherapy-related exacerbation of ILD. Multivariate analysis demonstrated that clinical stage was a significantly independent prognostic factor (hazard ratio 0.517; 95 % confidence interval 0.314–0.842, p = 0.0079). Patients with clinical stage IV or recurrence after surgical resection showed poor prognosis (median survival time 8.5 months).

Conclusions

Our study suggests that the prognosis of NSCLC patients with ILD is poor. The risk of exacerbation of ILD in patients treated with platinum-based chemotherapy as the first-line treatment was slightly lower than in previous reports.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  CAS  PubMed  Google Scholar 

  2. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128

    Article  CAS  PubMed  Google Scholar 

  3. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  4. Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-Positive lung cancer. N Engl J Med 368:2385–2394

    Article  CAS  PubMed  Google Scholar 

  5. Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18–S23

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348–1357

    Article  PubMed  Google Scholar 

  7. Azzoli CG, Temin S, Aliff T et al (2011) 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831

    Article  PubMed Central  PubMed  Google Scholar 

  8. Besse B, Adjei A, Baas P et al (2014) 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease. Ann Oncol 25:1475–1484

    Article  PubMed  Google Scholar 

  9. Pavlakis N, Bell DR, Millward MJ et al (1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286–291

    Article  CAS  PubMed  Google Scholar 

  10. Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847–853

    Article  PubMed  Google Scholar 

  11. Yoh K, Kenmotsu H, Yamaguchi Y et al (2010) Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 5:1435–1438

    Article  PubMed  Google Scholar 

  12. Kenmotsu H, Naito T, Kimura M et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6:1242–1246

    Article  PubMed  Google Scholar 

  13. Collard HR, Moore BB, Flaherty KR et al (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636–643

    Article  PubMed Central  PubMed  Google Scholar 

  14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  15. Shukuya T, Ishiwata T, Hara M et al (2010) Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30:4357–4361

    CAS  PubMed  Google Scholar 

  16. Kinoshita T, Azuma K, Sasada T et al (2012) Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 4:477–482

    PubMed Central  CAS  PubMed  Google Scholar 

  17. Okuda K, Hirose T, Oki Y et al (2012) Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer Res 32:5475–5480

    CAS  PubMed  Google Scholar 

  18. Watanabe N, Taniguchi H, Kondoh Y et al (2013) Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration 85:326–331

    Article  CAS  PubMed  Google Scholar 

  19. Minegishi Y, Takenaka K, Mizutani H et al (2009) Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 48:665–672

    Article  PubMed  Google Scholar 

  20. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323

    Article  CAS  PubMed  Google Scholar 

  21. Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28:5240–5246

    Article  CAS  PubMed  Google Scholar 

  22. Ohe Y, Yamamoto S, Suzuki K et al (2001) Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37:54–63

    Article  CAS  PubMed  Google Scholar 

  23. Sanuki N, Ono A, Komatsu E et al (2012) Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res 53:110–116

    Article  PubMed  Google Scholar 

  24. Minegishi Y, Sudoh J, Kuribayasi H et al (2011) The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71:70–74

    Article  PubMed  Google Scholar 

  25. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  26. Tamiya A, Naito T, Miura S et al (2012) Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 32:1103–1106

    PubMed  Google Scholar 

  27. Kuribayashi K, Voss S, Nishiuma S et al (2012) Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. Lung Cancer 75:353–359

    Article  PubMed  Google Scholar 

  28. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304

    Article  Google Scholar 

Download references

Conflict of interest

The authors declare no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Hirotsugu Kenmotsu, Tateaki Naito, Ryo Ko, Akira Ono, Kazushige Wakuda, Hisao Imai, Tetsuhiko Taira, Haruyasu Murakami & Toshiaki Takahashi

  2. Clinical Trial Coordination Office, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Japan

    Keita Mori

  3. Division of Diagnostic Radiology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Japan

    Masahiro Endo

Authors
  1. Hirotsugu Kenmotsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tateaki Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keita Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryo Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akira Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazushige Wakuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hisao Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsuhiko Taira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Haruyasu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiro Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirotsugu Kenmotsu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kenmotsu, H., Naito, T., Mori, K. et al. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 75, 521–526 (2015). https://doi.org/10.1007/s00280-014-2670-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2670-y

Keywords

Search

Navigation